182 related articles for article (PubMed ID: 34605947)
1. Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial.
Laterre PF; Pickkers P; Marx G; Wittebole X; Meziani F; Dugernier T; Huberlant V; Schuerholz T; François B; Lascarrou JB; Beishuizen A; Oueslati H; Contou D; Hoiting O; Lacherade JC; Chousterman B; Pottecher J; Bauer M; Godet T; Karakas M; Helms J; Bergmann A; Zimmermann J; Richter K; Hartmann O; Pars M; Mebazaa A;
Intensive Care Med; 2021 Nov; 47(11):1284-1294. PubMed ID: 34605947
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, placebo-controlled, randomised, multicentre, proof-of-concept and dose-finding phase II clinical trial to investigate the safety, tolerability and efficacy of adrecizumab in patients with septic shock and elevated adrenomedullin concentration (AdrenOSS-2).
Geven C; Blet A; Kox M; Hartmann O; Scigalla P; Zimmermann J; Marx G; Laterre PF; Mebazaa A; Pickkers P
BMJ Open; 2019 Feb; 9(2):e024475. PubMed ID: 30782906
[TBL] [Abstract][Full Text] [Related]
3. Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock:
van Lier D; Picod A; Marx G; Laterre PF; Hartmann O; Knothe C; Azibani F; Struck J; Santos K; Zimmerman J; Bergmann A; Mebazaa A; Pickkers P
Front Med (Lausanne); 2022; 9():1058235. PubMed ID: 36530868
[TBL] [Abstract][Full Text] [Related]
4. Single-dose of adrecizumab versus placebo in acute cardiogenic shock (ACCOST-HH): an investigator-initiated, randomised, double-blinded, placebo-controlled, multicentre trial.
Karakas M; Akin I; Burdelski C; Clemmensen P; Grahn H; Jarczak D; Keßler M; Kirchhof P; Landmesser U; Lezius S; Lindner D; Mebazaa A; Nierhaus A; Ocak A; Rottbauer W; Sinning C; Skurk C; Söffker G; Westermann D; Zapf A; Zengin E; Zeller T; Kluge S
Lancet Respir Med; 2022 Mar; 10(3):247-254. PubMed ID: 34895483
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects.
Geven C; van Lier D; Blet A; Peelen R; Ten Elzen B; Mebazaa A; Kox M; Pickkers P
Br J Clin Pharmacol; 2018 Sep; 84(9):2129-2141. PubMed ID: 29856470
[TBL] [Abstract][Full Text] [Related]
6. Circulating adrenomedullin estimates survival and reversibility of organ failure in sepsis: the prospective observational multinational Adrenomedullin and Outcome in Sepsis and Septic Shock-1 (AdrenOSS-1) study.
Mebazaa A; Geven C; Hollinger A; Wittebole X; Chousterman BG; Blet A; Gayat E; Hartmann O; Scigalla P; Struck J; Bergmann A; Antonelli M; Beishuizen A; Constantin JM; Damoisel C; Deye N; Di Somma S; Dugernier T; François B; Gaudry S; Huberlant V; Lascarrou JB; Marx G; Mercier E; Oueslati H; Pickkers P; Sonneville R; Legrand M; Laterre PF;
Crit Care; 2018 Dec; 22(1):354. PubMed ID: 30583748
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
François B; Lambden S; Fivez T; Gibot S; Derive M; Grouin JM; Salcedo-Magguilli M; Lemarié J; De Schryver N; Jalkanen V; Hicheur T; Garaud JJ; Cuvier V; Ferrer R; Bestle M; Pettilä V; Mira JP; Bouisse C; Mercier E; Vermassen J; Huberlant V; Vinatier I; Anguel N; Levy M; Laterre PF;
Lancet Respir Med; 2023 Oct; 11(10):894-904. PubMed ID: 37269870
[TBL] [Abstract][Full Text] [Related]
8. Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101).
Karakas M; Jarczak D; Becker M; Roedl K; Addo MM; Hein F; Bergmann A; Zimmermann J; Simon TP; Marx G; Lütgehetmann M; Nierhaus A; Kluge S
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32796765
[TBL] [Abstract][Full Text] [Related]
9. Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats.
Blet A; Deniau B; Geven C; Sadoune M; Caillard A; Kounde PR; Polidano E; Pickkers P; Samuel JL; Mebazaa A
Intensive Care Med Exp; 2019 May; 7(1):25. PubMed ID: 31093784
[TBL] [Abstract][Full Text] [Related]
10. Effects of the Non-Neutralizing Humanized Monoclonal Anti-Adrenomedullin Antibody Adrecizumab on Hemodynamic and Renal Injury in a Porcine Two-Hit Model.
Thiele C; Simon TP; Szymanski J; Daniel C; Golias C; Hartmann O; Struck J; Martin L; Marx G; Schuerholz T
Shock; 2020 Dec; 54(6):810-818. PubMed ID: 32554994
[TBL] [Abstract][Full Text] [Related]
11. Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis.
Geven C; Peters E; Schroedter M; Struck J; Bergmann A; McCook O; Radermacher P; Kox M; Pickkers P
Shock; 2018 Dec; 50(6):648-654. PubMed ID: 29324627
[TBL] [Abstract][Full Text] [Related]
12. Adrecizumab: an investigational agent for the biomarker-guided treatment of sepsis.
Deniau B; Takagi K; Asakage A; Mebazaa A
Expert Opin Investig Drugs; 2021 Feb; 30(2):95-102. PubMed ID: 33256482
[No Abstract] [Full Text] [Related]
13. The I-MICRO trial, Ilomedin for treatment of septic shock with persistent microperfusion defects: a double-blind, randomized controlled trial-study protocol for a randomized controlled trial.
Legrand M; Oufella HA; De Backer D; Duranteau J; Leone M; Levy B; Rossignol P; Vicaut E; Dépret F;
Trials; 2020 Jul; 21(1):601. PubMed ID: 32611377
[TBL] [Abstract][Full Text] [Related]
14. Preclinical safety evaluation of the adrenomedullin-binding antibody Adrecizumab in rodents, dogs and non-human primates.
Geven C; Kox M; Blet A; Mebazaa A; Schroedter M; Struck J; Bergmann A; Pickkers P
Toxicol Appl Pharmacol; 2019 Apr; 369():1-16. PubMed ID: 30822437
[TBL] [Abstract][Full Text] [Related]
15. Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
François B; Wittebole X; Ferrer R; Mira JP; Dugernier T; Gibot S; Derive M; Olivier A; Cuvier V; Witte S; Pickkers P; Vandenhende F; Garaud JJ; Sánchez M; Salcedo-Magguilli M; Laterre PF
Intensive Care Med; 2020 Jul; 46(7):1425-1437. PubMed ID: 32468087
[TBL] [Abstract][Full Text] [Related]
16. Selepressin, a novel selective vasopressin V
Russell JA; Vincent JL; Kjølbye AL; Olsson H; Blemings A; Spapen H; Carl P; Laterre PF; Grundemar L
Crit Care; 2017 Aug; 21(1):213. PubMed ID: 28807037
[TBL] [Abstract][Full Text] [Related]
17. Vascular Effects of Adrenomedullin and the Anti-Adrenomedullin Antibody Adrecizumab in Sepsis.
Geven C; Bergmann A; Kox M; Pickkers P
Shock; 2018 Aug; 50(2):132-140. PubMed ID: 29324626
[TBL] [Abstract][Full Text] [Related]
18. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study.
Briegel J; Forst H; Haller M; Schelling G; Kilger E; Kuprat G; Hemmer B; Hummel T; Lenhart A; Heyduck M; Stoll C; Peter K
Crit Care Med; 1999 Apr; 27(4):723-32. PubMed ID: 10321661
[TBL] [Abstract][Full Text] [Related]
19. Preliminary safety and efficacy of L-carnitine infusion for the treatment of vasopressor-dependent septic shock: a randomized control trial.
Puskarich MA; Kline JA; Krabill V; Claremont H; Jones AE
JPEN J Parenter Enteral Nutr; 2014 Aug; 38(6):736-43. PubMed ID: 23851424
[TBL] [Abstract][Full Text] [Related]
20. Adrenomedullin in heart failure: pathophysiology and therapeutic application.
Voors AA; Kremer D; Geven C; Ter Maaten JM; Struck J; Bergmann A; Pickkers P; Metra M; Mebazaa A; Düngen HD; Butler J
Eur J Heart Fail; 2019 Feb; 21(2):163-171. PubMed ID: 30592365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
